Article

Natural Supplements for Major Depression?

Omega-3 supplements are an effective treatment for patients with major depression who are not suffering from comorbid anxiety.

In the largest study ever to assess the efficacy of omega-3s for treating depression, researchers from the University of Montreal—led by Dr. François Lespérance—found that patients with major depression who were not suffering from comorbid anxiety benefited significantly from omega-3 supplements.

For these patients, “omega-3 supplementation was superior to placebo, with an adjusted mean difference of 3.17 points on the [Inventory of Depressive Symptomatology]-SR30 (95% CI, 0.89 to 5.45; P = .007) and 1.93 points (95% CI, 0.50 to 3.36; P = .008) on the” Montgomery-Åsberg Depression Rating Scale.

Between October 2005 and January 2009, 432 male and female participants with major unipolar depression participated in the randomized, double-blind study. Over an 8-week period, half of the participants took three capsules per day of OM3 Emotional Balance, a fish oil supplement containing high concentrations of eicosapentaenoic acid (EPA), while the other half of patients were given an identical placebo capsule that contained sunflower oil flavored by a small quantity of fish oil. During the 8 weeks, the participants were given omega-3s at doses of 1050 mg of EPA and 150 mg of DHA each day; the researchers did not specify whether taking the supplements at higher doses or for a longer time would provide different results.

“In this heterogeneous sample of patients with MDE, there was only a trend toward superiority of omega-3 supplementation over placebo in reducing depressive symptoms,” the researchers wrote in the Journal of Clinical Psychiatry. “However, there was a clear benefit of omega-3 supplementation among patients with MDE without comorbid anxiety disorders.”

The team also included researchers from McGill University, Université Laval, and Queen's University.

Related Videos
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Geoffrey Grammer, MD, presenting slides
Robert Zalewski-Zaragoza, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.